ClinicalTrials.gg
CompletedNCT04830865Updated Mar 13, 2025

Adaptation and Validation of Frailty Scales in Intensive Care Units in Spain

An observational study in Frailty Syndrome, sponsored by Hospital Universitario Getafe. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Hospital Universitario Getafe · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
512
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Frailty with a site in Spain — 46 open to participants now, 54 under way, none of them phase 3. Frailty · Spain.

Enrollment
14th of 36
512 · median 432
Started
2019
with 12 others
Observational
36 of 132
11 open now
Registered
46th of 132
by date
Lead sponsor
6 of 132
Hospital Universitario Getafe

Among the 132 studies in Frailty with a site in Spain, this one is the 14th largest by enrollment of the 36 observational ones that give a count, is one of 13 that started in 2019, is one of 36 observational ones, and was the 46th registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

46 of the 132 studies in Frailty with a site in Spain are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Frailty with a site in Spain, or all of them as a file.
02

Study summary

Increased life expectancy leads to population aging, increased morbidities and aging of hospitalized patients. The acquisition of frailty leads to worse outcomes derived from hospitalization, but although frailty has been related to aging, young patients admitted to Intensive Care Units (ICU) with frailty have also been found to have worse outcomes than non-frail patients. This unfavorable evolution could be related to the acquisition of the post-uci syndrome (physical, mental and cognitive sequelae at discharge from the ICU), since high frailty scores favor this syndrome.

The use of frailty scales on admission to the ICU could provide early detection of patients most likely to develop post-ICU syndrome, regardless of age, and redirect our care to those who need it most. Some scales that measure frailty in elderly patients have been used in the ICU, but although they have been validated in their original language, they need to be adapted and validated in Spanish.

Objectives. Adaptation and validation of the Clinical Frailty Scale (CFS) and the FRAIL Scale in ICU patients of different ages, in women and in men.

Methodology. Study developed in two phases.Phase 1, adaptation to Spanish of the scales (translation, pilot, back-translation, correlation); Phase 2, analysis of their metric properties (Validity, Reliability, Sensitivity, Minimum important difference) by means of a multicenter observational study (7 ICUs in Spain), prospective, descriptive, of a cohort of critical patients with one-year follow-up (at 3, 6, 9 and 12 months after hospital discharge).

03

Conditions studied

  • Frailty Syndrome

Browse trials for

Keywords

  • Frailty
  • critical care
  • gender
  • reliability
  • validity
  • study transcultural
  • quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients who remain hospitalized for more than 48 hours in any of the 8 Spanish intensive care units participating in the study, they will be candidates for inclusion in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Critical care patients over 18 years who have given their consent personally.

Exclusion criteria

Exclusion Criteria:

  • Patients admitted with a diagnosis of present or imminent brain death,
  • readmissions previously included,
  • patients whose expected stay is less than 48 hours
  • patients with comunication problems
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
512 participants (actual)
Target follow-up
12 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Fragility scales's validation

    100% scale sensitivity

    Time frame: 2 years

Secondary outcomes

  1. Obtaining adapted scales to patients in intensive care units in Spain

    Through a process of cross-cultural, FRAIL scale will be implemented in spanish. Minimun value is 0 and maximum value is 5. Value of 0 is not frail, values of 1 or 2 is prefrail and values of 3 to 5 is frail.

    Time frame: 6 months

  2. Obtaining adapted scales to patients in intensive care units in Spain

    Through a process of cross-cultural adaptation, Clinical Frailty Scale (CFS) will be implemented in spanish. Minimun value is 0 and maximum value is 9. Values of 0 to 3 is not frail, values of 4 is vulnerable, and 5 or 9 is frail.

    Time frame: 6 months

  3. Assessment of the predictive, convergent and divergent validity of the scales obtained (with respect to the original ones)

    Using statistical tests, the validity of the scales will be estimated in relation to the variables which it should or should not have concordance and its predictive capacity.

    Time frame: 2 years

  4. Assessment of the interobserver and intraobserver reliability of the scales obtained (with respect to the original ones)

    Through statistical tests, the interobserver and intraobserver concordance between nurses and physicians will be estimated.

    Time frame: 2 years

  5. Assessment of the sensitivity to change of the scales obtained (with respect to the original ones)

    Through statistical tests, the floor and ceiling of the scales and the change in the score of the scales obtained between baseline and 3, 6, 9 and 12 months after hospital discharge will be assessed.

    Time frame: 1 year

  6. Assessment of the minimum important difference of the scales obtained

    The relevance of the change in the score on the scales will be assessed, from the point of view of the patient and the professionals, related to quality of life.

    Time frame: 2 years

07

Study locations

1 site
  • Hospital Universitario de Getafe
    Getafe, Madrid 28905, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Oct 2024, 60 months.

Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's 60 months is above that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2021
First posted
Apr 5, 2021
StartActual
Sep 15, 2019
Primary completionActual
Oct 5, 2024
CompletionActual
Oct 5, 2024
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04830865
Lead sponsor
Hospital Universitario Getafe
Collaborators
Instituto de Salud Carlos III
Responsible party
Susana Arias Rivera (Principal Investigator, Hospital Universitario Getafe) — Principal investigator
First posted
Apr 5, 2021
Start date
Sep 15, 2019
Primary completion
Oct 5, 2024
Completion
Oct 5, 2024
Last update
Mar 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion